Sandoz Aims For $6bn Biosimilar Business By 2030

Sandoz Has A 22% Share Of Global Biosimilars Market At Present

Fueled by a pipeline of more than 15 biosimilar candidates, Sandoz is aiming to treble the size of its $2bn global biosimilars business by 2030, targeting the US, Europe and Japan. Management spoke at length about the firm’s achievements and prospects during a meeting of parent Novartis’ management.

Green Pin In Year 2030
Sandoz has ambitions to treble the size of its biosimilar business by 2030 • Source: Shutterstock

Sandoz is aiming to take its $2bn global biosimilars business to a $5bn-$6bn business by 2030, with 15-plus molecules in the Novartis subsidiary’s pipeline and a lucrative wave of biosimilar opportunities on the horizon in the next decade.

“We have the number one position now in Europe in terms of market share for biosimilars. We’re number one in...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.